C07K - Peptides - Patents Sitemap

More topics under "C07K - Peptides" (616,656)
C07K 1 - General processes for the preparation of peptides (51,718)
C07K 11 - Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof (895)
C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526)
C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320)
C07K 17 - Carrier-bound or immobilised peptides; Preparation thereof (10,673)
C07K 19 - Hybrid peptides (29,428)
C07K 2 - Peptides of undefined number of amino acids; Derivatives thereof (4,723)
C07K 4 - Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof (2,102)
C07K 5 - Peptides having up to four amino acids in a fully defined sequence; Derivatives thereof (30,692)
C07K 7 - Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof (42,273)
C07K 9 - Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof (3,306)

Patents for C07K - Peptides (3,738)
01/2005
01/05/2005	EP1492808A2 Broad-spectrum in-vivo effective superantigen toxin antagonists based on the interaction between cd28 and the superantigen and uses thereof
12/2004
12/30/2004	US20040265323 Compositions comprising pathogen elicited epithelial chemoattractant (eicosanoid hepoxilin A3), inhibitors thereof and methods of use thereof
12/30/2004	DE10325752A1 Lektin-Konjugate Lectin conjugates
12/29/2004	WO2004113361A2 Novel prokineticin receptor isoforms and methods of use
12/29/2004	CN1181886C Application of TNF-derived peptides in the treatment of oedema
12/28/2004	US6835819 Sequences and their use
12/23/2004	WO2004111075A2 Alternative reading frame polypeptides for treatment
12/23/2004	WO2004111074A2 In vivo production of a clostridial neurotoxin light chain peptide
12/23/2004	WO2004110337A2 Cell permeable conjugates of peptides for inhibition of protein kinases
12/23/2004	WO2004074310A8 Mycobacterial diagnostics
12/23/2004	US20040259164 Capture and release based isotope tagged peptides and methods for using the same
12/23/2004	US20040258821 purification of aspartame or neotame slurries using water and compressed air, which forces impurities through filters, then recovering and dehydrating the crystals
12/23/2004	US20040258726 Methods and materials for nanocrystalline surface coatings and attachment of peptide amphiphile nanofibers thereon
12/23/2004	CA2563361A1 Cell permeable conjugates of peptides for inhibition of protein kinases
12/23/2004	CA2514288A1 Compositions and methods employing alternative reading frame polypeptides for the treatment of cancer and infectious disease
12/22/2004	EP1487479A2 Mutant glycoproteins
12/16/2004	WO2004108748A2 Growth arrest specific gene 6 peptides, antibodies, compositions, methods and uses
12/16/2004	WO2004108747A2 Lectin conjugates
12/16/2004	WO2004094459A3 Polypeptides related to natriuretic peptides and methods of their identification and use
12/16/2004	WO2004000872A9 Improved alphavirus vectors having attenuated virion structural proteins
12/16/2004	US20040254114 Genetic engineering
12/16/2004	US20040253241 Inducible ligand for alpha1beta1 integrin and uses
12/15/2004	CN1179973C HBV core antigen particles with multiple immunogenic components attached via peptide ligands
12/09/2004	WO2004106361A2 Peptides for metal ion affinity chromatogrpahy
12/09/2004	WO2004106360A2 Viral vectors with improved properties
12/09/2004	WO2004106359A2 Self-assembled peptide-amphiphiles & self-assembled peptide nanofiber networks presenting multiple signals
12/09/2004	WO2004028473A3 Synergistic compositions for the prevention and treatment of acquired immunodeficiency syndrome
12/09/2004	US20040248205 Major histocompatibility complex (MHC)-peptide arrays
12/07/2004	US6827937 HBV capsid-binding peptide immunogens
12/02/2004	WO2004104022A2 Compositions comprising pathogen elicited epithelial chemoattractant (eicosanoid hepoxilin a3), inhibitors thereof and methods of use thereof
12/02/2004	WO2004104019A2 Anti-inflammatory/anti-microbial peptides for use in dialysis
12/02/2004	WO2004104018A2 Compositions for delivering peptide yy and pyy agonists
12/02/2004	WO2004092201A3 Enhanced hiv-1 vaccines and methods for their use
12/02/2004	US20040242606 Anti-cancer cyclopenta (g)quinazoline compounds
12/02/2004	US20040241724 Immobilization method and kit therefor
12/02/2004	CA2525168A1 Compositions for delivering peptide yy and pyy agonists
12/01/2004	EP1482044A2 Multivariant IL-3 hematopoiesis fusion protein
12/01/2004	EP1481992A2 Humanized antibodies that sequester amyloid beta peptide
12/01/2004	EP1481989A1 A-33 related antigens and their pharmacological uses
12/01/2004	EP1257584B9 Humanized antibodies that sequester amyloid beta peptide
11/2004
11/25/2004	WO2004101597A2 Methods for the reduction of disulfide bonds
11/25/2004	WO2004074315A3 Analogues of glp-1
11/25/2004	WO2004072095A3 Cyclized peptides as exotoxin antagonists
11/25/2004	US20040234554 Hepatitis B virus crosslinked with immunogens, epitopes; capsid peptide binding to core protein; vaccine
11/24/2004	EP0656012B1 T cell epitopes of ryegrass pollen allergen
11/18/2004	WO2004099232A2 Selective r-cadherin antagonists and methods
11/18/2004	WO2004099231A2 Glycopegylation methods and proteins/peptides produced by the methods
11/18/2004	WO2004078778A3 PEPTIDES THAT SPECIFICALLY BIND HGF RECEPTOR (cMet) AND USES THEREOF
11/18/2004	US20040231013 Transgenic mouse expressing fluorescent protein for use of whole body imaging in comparative disease diagnosis and prognosis; colorimetric analysis
11/18/2004	US20040230043 Novel neurotrophic factors
11/18/2004	US20040229784 Administering peptide hormones derived from atrial natriuretic factors/peptides (ANP), atriopeptin, as anticarcinogenic agents
11/18/2004	US20040229354 Enhancement of humoral immune responses using a novel myeloid accessory cell
11/18/2004	CA2523932A1 Selective r-cadherin antagonists and methods
11/18/2004	CA2522345A1 Glycopegylation methods and proteins/peptides produced by the methods
11/17/2004	EP1476541A2 Novel cytokine zcytor17 ligand
11/17/2004	EP1476471A1 Nutraceuticals for the treatment, protection and restoration of connective tissues
11/17/2004	EP1476185A2 Antibodies to cd40
11/17/2004	EP1137667B1 Analogues of glp-1
11/17/2004	CN1547590A Humanized anti-LT-beta-R antibodies
11/17/2004	CN1547587A Process for the selection of HIV-1 subtype C isolates, selected HIV-1 subtype isolates, their genes and modifications and derivatives thereof
11/16/2004	CA2159109C Therapeutic uses of keratinocyte growth factor
11/16/2004	CA2059692C Pneumoccoccal polysaccharide conjugate vaccine
11/11/2004	WO2004096832A2 Novel antiangiogenic peptides
11/11/2004	WO2004058801A3 Modified vaccinia ankara expressing p53 in cancer immunotherapy
11/11/2004	WO2004052919A3 Peptide deformylase inhibitors
11/11/2004	WO2004020458A3 Assays and compositions for identifying agents that modulate the activity of deubiquitinating agents
11/11/2004	US20040225120 Process for purifying a compound
11/11/2004	US20040224896 STQ peptides
11/10/2004	CN1174753C Improved copolymer-1 composed of copolymers
11/04/2004	WO2004094461A2 Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
11/04/2004	WO2004094460A2 Polypeptides related to natriuretic peptides and methods of their identification and use
11/04/2004	WO2004094459A2 Polypeptides related to natriuretic peptides and methods of their identification and use
11/04/2004	WO2004094458A2 Major histocompatibility complex (mhc)-peptide arrays
11/04/2004	WO2004094457A2 Stable rgd peptidomimetic composition
11/04/2004	WO2004094456A2 Immuno-amplification
11/04/2004	WO2004094455A2 Prophylactic and therapeutic benefits of new class of immune stimulating peptides
11/04/2004	WO2004094454A2 Hla-a2 tumor associated antigen peptides and compositions
11/04/2004	WO2004094453A2 Filtration of dipeptide and dipeptide derivative sweeteners
11/04/2004	WO2004094452A2 Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus
11/04/2004	WO2004050681A3 Kinase modulators
11/04/2004	US20040219641 Comprises nucleotide sequences coding lipopolysaccharide induced tumor necrosis factor - alpha factor (LITAF) proteins for use in treatment and prevention of cell proliferative disorders; antitumor agents; immunotherapy
11/04/2004	US20040219142 Treatment of skin and nail disorders using TNFalpha inhibitors
11/04/2004	US20040219131 Interferon-alpha polypeptides and conjugates
11/04/2004	CA2522753A1 Immuno-amplification
11/04/2004	CA2522709A1 Polypeptides related to natriuretic peptides and methods of their identification and use
11/04/2004	CA2522703A1 Prophylactic and therapeutic benefits of new class of immune stimulating peptides
11/04/2004	CA2522670A1 Polypeptides related to natriuretic peptides and methods of their identification and use
11/02/2004	US6812021 Isolated from streptococcus; for preparation of therapeutics (vaccines) to immunize against microbial infection; urinary tract infections; drug screening
10/2004
10/28/2004	WO2004092201A2 Enhanced hiv-1 vaccines and methods for their use
10/28/2004	WO2004092199A2 Method for identifying modulators of g protein coupled receptor signaling
10/28/2004	WO2004092198A2 Compositions and methods for the modifying hypoxia induced gene regulation
10/28/2004	WO2004092197A2 Amyloid-specific peptides and uses thereof
10/28/2004	WO2004092196A2 Tie-2 modulators and methods of use
10/28/2004	WO2004092195A2 Dendritic cell binding proteins and uses thereof
10/28/2004	WO2004092194A2 Chimeric polypeptides and their use
10/28/2004	WO2004058798A9 Antimicrobial peptides
10/28/2004	WO2004055041A3 Defensin-inducing peptides from fusobacterium
10/28/2004	WO2003104262A3 Gp41 peptides and methods based-thereon for inhibiting hiv fusion to target cells
10/28/2004	US20040214776 (truncated GDNF) proteins that promote dopamine uptake by dopaminergic cells and promote the survival of nerve cells
10/28/2004	US20040214774 inhibiting accumulation of amyloid- beta deposits by administering an agent which inhibits interaction between amyloid- beta and proteins which chaperone amyloid- beta, such as alpha chymotrypsin or apolipoprotein E

1 ... 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 ... 38